Literature DB >> 8846627

Pharmacokinetic-pharmacodynamic relationships for benzodiazepines.

B E Laurijssens1, D J Greenblatt.   

Abstract

This article reviews the literature on the plasma concentration-effect relationships for benzodiazepines, in humans and in experimental animals. Only literature that explicitly links pharmacokinetics to pharmacodynamics is included. The following questions are evaluated. Can concentration-effect relationships be demonstrated? If so, are these relations stable? Are the influences of specific factors such as age and disease on these relationships established? It is clear that, when studies are conducted and interpreted appropriately, relations can be found for a wide range of benzodiazepine effects. These include objective measures such as electroencephalography, semisubjective measures such as psychomotor performance, and subjective measures such as mood/sedation scales. A generally applicable model of the relationship which will allow prediction of effect is, however, not yet established. The relationship appears to be dependent on route and rate of administration, because of factors such as distributional delay, formation of active metabolites and, probably, acute tolerance. Furthermore, intra- and interindividual variability is considerable, probably due to varying experimental conditions and intrinsic interindividual differences. The limited data available on factors influencing the plasma concentration-effect relationships for benzodiazepines demonstrate clear changes in the pharmacodynamics after multiple doses, suggesting the development of tolerance, and a subsensitivity in patients with panic disorder. The influence of factors such as age, disease and drug interactions on the pharmacokinetic-pharmacodynamic relationship remains less clear.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8846627     DOI: 10.2165/00003088-199630010-00004

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  108 in total

Review 1.  Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs.

Authors:  J W Mandema; M Danhof
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

2.  The influence of dosage time of midazolam on its pharmacokinetics and effects in humans.

Authors:  R Koopmans; J Dingemanse; M Danhof; G P Horsten; C J van Boxtel
Journal:  Clin Pharmacol Ther       Date:  1991-07       Impact factor: 6.875

Review 3.  Kinetic-effect models and their applications.

Authors:  J Grevel
Journal:  Pharm Res       Date:  1987-04       Impact factor: 4.200

4.  Plasma concentrations of diazepam and of its metabolite N-desmethyldiazepam in relation to anxiolytic effect.

Authors:  H H Dasberg; E van der Kleijn; J P Guelen; H M van Praag
Journal:  Clin Pharmacol Ther       Date:  1974-05       Impact factor: 6.875

5.  Effects of oral contraceptives on diazepam-induced psychomotor impairment.

Authors:  E H Ellinwood; M E Easler; M Linnoila; D W Molter; D G Heatherly; T D Bjornsson
Journal:  Clin Pharmacol Ther       Date:  1984-03       Impact factor: 6.875

6.  Plasma alprazolam concentrations. Relation to efficacy and side effects in the treatment of panic disorder.

Authors:  D J Greenblatt; J S Harmatz; R I Shader
Journal:  Arch Gen Psychiatry       Date:  1993-09

7.  Alprazolam in the elderly: pharmacokinetics and pharmacodynamics during multiple dosing.

Authors:  P D Kroboth; J W McAuley; R B Smith
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

8.  Pharmacodynamics of triazolam after intravenous administration.

Authors:  R B Smith; P D Kroboth; P D Varner
Journal:  J Clin Pharmacol       Date:  1987-12       Impact factor: 3.126

9.  Pharmacodynamic interaction between midazolam and a low dose of ethanol in vivo.

Authors:  C Hoyo-Vadillo; J W Mandema; M Danhof
Journal:  Life Sci       Date:  1995       Impact factor: 5.037

10.  Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia.

Authors:  I M Lesser; R B Lydiard; E Antal; R T Rubin; J C Ballenger; R DuPont
Journal:  Am J Psychiatry       Date:  1992-11       Impact factor: 18.112

View more
  8 in total

Review 1.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

2.  Pharmacodynamic response profiles of anxiolytic and sedative drugs.

Authors:  Xia Chen; Freerk Broeyer; Marieke de Kam; Joke Baas; Adam Cohen; Joop van Gerven
Journal:  Br J Clin Pharmacol       Date:  2017-03-17       Impact factor: 4.335

3.  The non-benzodiazepine anxiolytic drug etifoxine causes a rapid, receptor-independent stimulation of neurosteroid biosynthesis.

Authors:  Jean Luc do Rego; David Vaudry; Hubert Vaudry
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

Review 4.  Pharmacokinetic optimization of benzodiazepine therapy for acute seizures. Focus on delivery routes.

Authors:  E Rey; J M Tréluyer; G Pons
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

Review 5.  Tolerance to allopregnanolone with focus on the GABA-A receptor.

Authors:  Sahruh Turkmen; Torbjorn Backstrom; Goran Wahlstrom; Lotta Andreen; Inga-Maj Johansson
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

6.  Pharmocokinetics and pharmacodynamics of single-dose triazolam: electroencephalography compared with the Digit-Symbol Substitution Test.

Authors:  David J Greenblatt; Lu Gan; Jerold S Harmatz; Richard I Shader
Journal:  Br J Clin Pharmacol       Date:  2005-09       Impact factor: 4.335

7.  Citalopram concentrations and response in obsessive-compulsive disorder. Preliminary results.

Authors:  Silvio R Bareggi; L Bianchi; R Cavallaro; M Gervasoni; F Siliprandi; L Bellodi
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 8.  Electroencephalogram-based pharmacodynamic measures: a review.

Authors:  Michael Bewernitz; Hartmut Derendorf
Journal:  Int J Clin Pharmacol Ther       Date:  2012-03       Impact factor: 1.366

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.